Boston Scientific Appoints Starbucks CFO and Outgoing Takeda CEO to Board
Boston Scientific elected Starbucks CFO Cathy Smith and Takeda CEO Christophe Weber to its board effective February 18, 2026, replacing John Sununu and Yoshiaki Fujimori ahead of the 2026 annual meeting. Smith’s finance expertise and Weber’s global pharma leadership could enhance strategic execution and market expansion.
1. Board Election Details
On February 18, 2026, Boston Scientific elected Cathy Smith and Christophe Weber to its board of directors, filling seats vacated by John Sununu and Yoshiaki Fujimori ahead of the 2026 annual meeting.
2. Cathy Smith Profile
Smith currently serves as chief financial officer of Starbucks and previously held CFO positions at Nordstrom, Target, Express Scripts, Walmart and Bright Health, bringing deep finance, strategy and operational expertise.
3. Christophe Weber Profile
Weber, Takeda Pharmaceutical’s president and CEO since 2015 retiring in June 2026, adds extensive global leadership experience, having held senior roles at Takeda and GlaxoSmithKline.
4. Strategic Implications
The addition of Smith’s financial acumen and Weber’s pharma governance experience is expected to strengthen Boston Scientific’s strategic execution, innovation pipeline oversight and global market positioning.